According to these considerations, also in the setting of neoplastic disease, we could hypothesize that high FVIIa–AT plasma levels may allow us to identify patients with cancer overexpressing TF who can receive major benefits from such treatment approaches or specifically from anti-TF molecularly targeted treatment against malignant cells (Figure 4). The gene discussed is TF; the disease is cancer.